No products in the cart.
Atopic dermatitis activity is not associated with cardiovascular risk
1. In this cohort study, more active or severe atopic dermatitis (AD) in children was not associated with a greater ...
Tag: dermatology
Oral remibrutinib hits Phase 3 primary endpoint for inducible hives
1. Oral remibrutinib successfully met its primary endpoint in the Phase III RemIND trial, delivering significant symptom relief for chronic ...
2MM: AI Roundup –Lilly launches TuneLab AI drug discovery, smart wound healing bandage, and Punjab cancer screening [September 25th, 2025]
Lilly unveils TuneLab AI platform for biotechs On September 9, 2025, Eli Lilly officially unveiled TuneLab, a federated AI platform ...
Artificial intelligence matches dermatologists in melanoma diagnosis
1. Artificial intelligence triage for melanoma shows more than 90 percent sensitivity and is now in trials within the National ...
2MM: AI Roundup –Dermatology accuracy, faster drug discovery, heart disease detection, and global medical training [September 11th, 2025]
Google’s AI matches dermatologists in melanoma diagnosis England’s health service is piloting an artificial intelligence tool called Deep Ensemble for ...
Microneedling with tranexamic acid may improve outcomes for patients with melasma
1. Among patients with melasma, microneedling with tranexamic acid was superior to microneedling with metformin or the control treatment in ...
Remibrutinib alleviates symptoms in chronic spontaneous urticaria resistant to H1-antihistamines
1. In this randomized controlled trial, among patients with chronic spontaneous urticaria who continue to have symptoms while on second-generation ...
Neoadjuvant ipilimumab plus nivolumab improves event-free survival in stage III melanoma
1. In this randomized controlled trial, two cycles of neoadjuvant ipilimumab plus nivolumab resulted in longer event-free survival than adjuvant ...
Use of certain biologics or disease modifying antirheumatic drugs may be associated with cancer risk
1. The use of rituximab, abatacept and Janus kinase inhibitors (JAKis) in individuals with rheumatoid arthritis (RA) was associated with ...
Adjuvant dabrafenib and trametinib improve survival in stage III melanoma
1. After almost 10 years of follow-up, adjuvant dabrafenib and trametinib improved relapse-free and metastasis-free survival compared to placebo in ...
